Table 3.
Small RNA-based therapeutics in clinical trials (adapted from[71])
| Gene target | Drug type | Drug name | Clinical phase | Notes |
|---|---|---|---|---|
| Bcl-2 |
LNA-oligo |
SPC2996 |
I/II |
CLL |
| Immunoproteasome β-subunits LMP2, LMP7 and MECL1 |
siRNA |
Proteasome siRNA |
I |
Metastatic lymphoma |
| PLK1 |
siRNA |
PLK SNALP |
pre-clinical |
|
| M2 subunit of ribonucleotide reductase |
siRNA |
CALAA-01 |
I |
Solid tumors |
| PKN3 |
siRNA |
Atu027 |
I |
Solid tumors |
| KSP and VEGF |
siRNA |
ALN-VSP |
I |
Solid tumors |
| Survivin |
LNA-oligo |
EZN3042 |
I/II |
Solid tumors |
| HIF-1α |
LNA-oligo |
EZN2968 |
I/II |
Solid tumors |
| Furin |
shRNA |
FANG vaccine |
I |
Solid tumors |
| eiF-4E |
LNA-oligo |
elF-4E ASO |
I |
Solid tumors |
| Survivin | LNA-oligo | Survivin ASO | II | Solid tumors |